Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients

E. Fisher, R. A. Rudick, G. Cutter, M. Baier, D. Miller, B. Weinstock-Guttman, Michele Mass, D. S. Dougherty, N. A. Simonian

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNβ-I a (Avonex) in relapsing - remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing - remitting MS.

Original languageEnglish (US)
Pages (from-to)373-377
Number of pages5
JournalMultiple Sclerosis
Volume6
Issue number6
DOIs
StatePublished - 2000

Fingerprint

Multiple Sclerosis
Atrophy
Brain
Disease Progression
Relapsing-Remitting Multiple Sclerosis
Pathologic Processes
Random Allocation
Magnetic Resonance Imaging
Research

Keywords

  • Brain atrophy
  • Magnetic resonance imaging
  • Multiple sclerosis

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Fisher, E., Rudick, R. A., Cutter, G., Baier, M., Miller, D., Weinstock-Guttman, B., ... Simonian, N. A. (2000). Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis, 6(6), 373-377. https://doi.org/10.1191/135245800701566331

Relationship between brain atrophy and disability : An 8-year follow-up study of multiple sclerosis patients. / Fisher, E.; Rudick, R. A.; Cutter, G.; Baier, M.; Miller, D.; Weinstock-Guttman, B.; Mass, Michele; Dougherty, D. S.; Simonian, N. A.

In: Multiple Sclerosis, Vol. 6, No. 6, 2000, p. 373-377.

Research output: Contribution to journalArticle

Fisher, E, Rudick, RA, Cutter, G, Baier, M, Miller, D, Weinstock-Guttman, B, Mass, M, Dougherty, DS & Simonian, NA 2000, 'Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients', Multiple Sclerosis, vol. 6, no. 6, pp. 373-377. https://doi.org/10.1191/135245800701566331
Fisher, E. ; Rudick, R. A. ; Cutter, G. ; Baier, M. ; Miller, D. ; Weinstock-Guttman, B. ; Mass, Michele ; Dougherty, D. S. ; Simonian, N. A. / Relationship between brain atrophy and disability : An 8-year follow-up study of multiple sclerosis patients. In: Multiple Sclerosis. 2000 ; Vol. 6, No. 6. pp. 373-377.
@article{fe1f25cda4204ae28131f89d8a332718,
title = "Relationship between brain atrophy and disability: An 8-year follow-up study of multiple sclerosis patients",
abstract = "Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNβ-I a (Avonex) in relapsing - remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing - remitting MS.",
keywords = "Brain atrophy, Magnetic resonance imaging, Multiple sclerosis",
author = "E. Fisher and Rudick, {R. A.} and G. Cutter and M. Baier and D. Miller and B. Weinstock-Guttman and Michele Mass and Dougherty, {D. S.} and Simonian, {N. A.}",
year = "2000",
doi = "10.1191/135245800701566331",
language = "English (US)",
volume = "6",
pages = "373--377",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Relationship between brain atrophy and disability

T2 - An 8-year follow-up study of multiple sclerosis patients

AU - Fisher, E.

AU - Rudick, R. A.

AU - Cutter, G.

AU - Baier, M.

AU - Miller, D.

AU - Weinstock-Guttman, B.

AU - Mass, Michele

AU - Dougherty, D. S.

AU - Simonian, N. A.

PY - 2000

Y1 - 2000

N2 - Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNβ-I a (Avonex) in relapsing - remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing - remitting MS.

AB - Brain atrophy measurement can provide an estimate of the amount of tissue destruction due to the pathologic processes in multiple sclerosis. The potential usefulness of atrophy as a marker of disease progression depends upon the concurrent and predictive relationships between atrophy and disability. A follow-up study was performed to measure atrophy and disability scores in patients from the Multiple Sclerosis Collaborative Research Group's phase III trial of IFNβ-I a (Avonex) in relapsing - remitting multiple sclerosis. New data were obtained on 160 out of 172 eligible patients from the original trial were enrolled in the follow-up study approximately 8 years after randomization. The follow-up visit consisted of several tests and questionnaires including a clinical exam to determine Expanded Disability Status Score (EDSS) and Multiple Sclerosis Functional Composite (MSFC), and a magnetic resonance imaging exam to calculate the brain parenchymal fraction. Brain parenchymal fraction was correlated with both EDSS and MSFC at each of the four time points for which data were available (baseline 1, 2 and 8 years). Furthermore, the change in BPF was correlated with the changes in disability scores from the end of the phase III trial to the follow-up exam. These data suggest that brain atrophy may be a useful and clinically relevant marker of disease progression in relapsing - remitting MS.

KW - Brain atrophy

KW - Magnetic resonance imaging

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0034490261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034490261&partnerID=8YFLogxK

U2 - 10.1191/135245800701566331

DO - 10.1191/135245800701566331

M3 - Article

C2 - 11212131

AN - SCOPUS:0034490261

VL - 6

SP - 373

EP - 377

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -